Jci_page_head_homepage_01 Jci_page_head_homepage_02
Bertrand Huard, Thomas McKee, Carine Bosshard, Stéphane Durual, Thomas Matthes, Samir Myit, Olivier Donze, Christophe Frossard, Carlo Chizzolini, Christiane Favre, Rudolf Zubler, Jean Philippe Guyot, Pascal Schneider, Eddy Roosnek
Published in Volume 118, Issue 8
J Clin Invest. 2008; 118(8):2887–2895 doi:10.1172/JCI33760
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 1
In vitro prosurvival role for APRIL in tonsillar plasma cells.

(A) APRIL-receptor expression on tonsillar plasma cells. The histograms show the expression of the indicated receptors on cells from the CD19+CD38highcytosplasmic-Ig+ (Cyt-Ig+) subset in the top left dot plot (rectangle). Similar results were obtained with tonsil cell suspensions from 8 patients. (B) CD19+CD38+ and CD19+CD38low/– tonsillar B cells (top panel, rectangles) were purified and incubated in medium containing ACRP-APRIL or control ACRP, both at 3 μg/ml. The number of viable cells was counted by trypan-blue exclusion every day for 4 days (bottom panel). Data are presented as mean ± SD. (C) Intracellular expression of bcl-2, bcl-xL, and mcl-1 was analyzed by flow cytometry on purified CD19+CD38+ at the initiation of the culture and after 4 days of culture with ACRP-APRIL or control ACRP. Dotted lines correspond to isotype control staining. (D) Binding of APRILA88 and APRILH98 to plastic-coated HSPG (1 μg/ml) was revealed with the Aprily-5 mAb (1 μg/ml) (top panel). CD19+CD38+ tonsillar plasma cells were incubated in plastic wells coated with HSPG- or HSPG-binding APRILA88 for 4 days. Intracellular bcl-2 expression was analyzed as in C (bottom panel). Data are representative of 2 independent experiments performed with 2 different donors. Sn, supernatant.